The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

被引：0
作者：
Xu, Jinyun [1 ,2 ]
Gu, Jiaowei [2 ]
Zhao, Yan [2 ]
Meng, Huihua [1 ]
Du, Li'an [1 ]
Zhang, Ruibo [2 ]
Jiang, Hao [2 ]
Luo, Jianming [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning, Guangxi, Peoples R China
[2] Hubei Univ Med, Taihe Hosp, Dept Pediat, Shiyan, Hubei, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 58期
关键词：
BIM; chronic myeloid leukemia; tyrosine kinase inhibitor; genetic polymorphism; drug resistance; DIAGNOSED CHRONIC-PHASE; PATIENTS RECEIVING IMATINIB; FOLLOW-UP; CYTOGENETIC RESPONSES; INTRINSIC RESISTANCE; 1ST-LINE TREATMENT; TYROSINE KINASE; BIM; DASATINIB; NILOTINIB;
D O I：
10.18632/oncotarget.21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 East Asian patients were identified from these electronic databases. The methodological quality of one included trial was high, and the others were moderate. Meta-analysis showed that the rate of TKI resistance between the BIM deletion and wild-type group were no statistical significance (OR = 1.24, 95% CI 0.79-1.95). In conclusion, BIM deletion may not a predictor of TKI resistance in CML individuals in East Asia.
引用
收藏
页码：99041 / 99048
页数：8
相关论文
共 50 条
  • [41] Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia
    Patel, Kinjal D.
    De, Maitri
    Jethva, Disha D.
    Rathod, Bharati S.
    Patel, Prabhudas S.
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 51 - 58
  • [42] t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia
    Dencic-Fekete, Marija
    Dordevic, Vesna
    Storlazzi, Clelia Tiziana
    Jankovic, Gradimir
    Bogdanovic, Andrija
    Jovanovic, Jelica
    Rocchi, Mariano
    Todoric-Zivanovic, Biljana
    Strnad, Milica
    Gotic, Mirjana
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (04) : 508 - 512
  • [43] t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia
    Marija Denčić-Fekete
    Vesna Đorđević
    Clelia Tiziana Storlazzi
    Gradimir Janković
    Andrija Bogdanović
    Jelica Jovanović
    Mariano Rocchi
    Biljana Todorić-Živanović
    Milica Strnad
    Mirjana Gotić
    International Journal of Hematology, 2009, 89 : 508 - 512
  • [44] Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis
    Kim, Jinchul
    Park, Jisun
    Moon, Yeonsook
    Choi, Suk Jin
    Lim, Joo Han
    Lee, Moon Hee
    Cho, Jinhyun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 683 - 689
  • [45] Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis
    Kobayashi, Yukio
    Sakamaki, Hisashi
    Fujisawa, Shin
    Ando, Kiyoshi
    Yamamoto, Kazuhito
    Okada, Masaya
    Ishizawa, Kenichi
    Nagai, Tadashi
    Miyawaki, Syuichi
    Motoji, Toshiko
    Usui, Noriko
    Iida, Shinsuke
    Taniwaki, Masafumi
    Uoshima, Nobuhiko
    Seriu, Taku
    Ohno, Ryuzo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (06) : 745 - 749
  • [46] First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis
    Gurion, Ronit
    Raanani, Pia
    Vidal, Liat
    Leader, Avi
    Gafter-Gvili, Anat
    ACTA ONCOLOGICA, 2016, 55 (9-10) : 1077 - 1083
  • [47] Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
    Cortes, Jorge E.
    Nicolini, Franck E.
    Wetzler, Meir
    Lipton, Jeffrey H.
    Akard, Luke
    Craig, Adam
    Nanda, Nisha
    Benichou, Annie-Claude
    Leonoudakis, Janis
    Khoury, H. Jean
    Hochhaus, Andreas
    Baccarani, Michele
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (05) : 584 - 591
  • [48] Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population
    Cereja-Pantoja, Karla Beatriz Cardias
    Azevedo, Tereza Cristina de Brito
    Vinagre, Lui Wallacy Morikawa Souza
    de Moraes, Francisco Cezar Aquino
    Nunes, Giovanna Gilioli da Costa
    Monte, Natasha
    de Alcantara, Angelica Leite
    Cohen-Paes, Amanda
    Fernandes, Marianne Rodrigues
    dos Santos, Sidney Emanuel Batista
    de Assumpcao, Paulo Pimentel
    dos Santos, Andrea Kely Ribeiro
    Burbano, Rommel Mario Rodriguez
    Guerrero, Raquel Cruz
    Carracedo, Angel
    dos Santos, Ney Pereira Carneiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 387 - 395
  • [49] Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - Evaluation of response and resistance
    Paschka, P
    Merx, K
    Hochhaus, A
    ACTA HAEMATOLOGICA, 2004, 112 (1-2) : 85 - 92
  • [50] Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors
    Ursan, Lulia D.
    Jiang, Ruixuan
    Pickard, Evan M.
    Lee, Todd A.
    Ng, Daniel
    Pickard, A. Simon
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (02) : 114 - 122
12345